[This article was reported on "Radar M," a paid media outlet specializing in the capital market in Mail Business, on June 26 (14:53)]
Remedy, a low-dose and ultra-small X-ray solution company, announced on the 26th that it has confirmed the final offering price at 20,700 won, the upper end of the desired range (17,800 won to 27,700 won) in a demand forecast for domestic and foreign institutional investors.
2,246 domestic and foreign institutions participated in the demand forecast conducted by Remedy from the 17th to the 23rd, recording a competition ratio of 1,146 to 1. 99.96% of participating organizations offered prices above the upper end of the desired range.
The total public offering amount following the determination of the public offering price is 24.8 billion won, and the expected market capitalization after listing is 157.1 billion won. The listing organizer is KB Securities.
Based on low-dose, small-scale, and high-quality X-ray source technology, Remedy developed and commercialized medical handheld X-rays, industrial non-destructive inspection equipment, and core X-ray components.
The company plans to focus the funds secured by the listing on upgrading R&D, expanding production capacity (CAPA), and strengthening its overseas sales network.
The goal is to increase the ability to respond to overseas orders by introducing automation facilities and to incorporate AI solutions into hardware package products.
"With this listing, we will expand the X-ray solutions needed in the medical field and expand our business area to the industrial non-destructive testing market," said Cho Bong-ho, CEO of Remedy.
